If you work in a veterinary practice or in the pet industry or in a business that supplies goods or services to the industry and you have something to say - why not become a 'Guest Blogger'?
For more information click here to read our: Guidelines for Guest Bloggers
PharmAust’s drug Monepantel (MPL) has demonstrated effective anti-cancer activity and minimal side effects in the latest Phase 2 trials of pet dogs with untreated B-cell lymphoma.
Further recruitment of pet dogs with untreated B cell lymphoma will allow a successful Phase 2 evaluation to be completed, and lead to the commencement of a subsequent Phase 3 registration trial.
A new MPL trial site is now open at Vets Albury Wodonga – Petfocus Vetcare in Albury NSW. It is the closest clinic to canine participants from the Melbourne area until PharmAust can secure a site in Victoria.
PharmAust is calling for Veterinary Clinics in the Melbourne area interested in participating in the trial to contact the Principal Investigator, Dr Kim Agnew at kim@kapconsulting.com.au
For information on all the current trial centres and trial entry criteria, please visit here.
You can download a PDF of the trial sites here
To date, trial data show dogs are living 3 times longer than on prednisolone and have a good quality of life*. Post-trial, some veterinarians and the respective pet owners have elected to continue the MPL treatment and, sometimes, in combination with prednisolone.
MPL is already approved for veterinary use as an anti-worming agent in sheep. PharmAust is aiming to repurpose MPL as a safe and effective cancer treatment.
LISTEN Dr Kim Agnew, Principal Investigator talks more about the MPL trial in a Pet Industry News podcast (27 March 2023).
Once the pet is diagnosed with lymphoma and formally enrolled in the study, PharmAust will cover all clinical trial costs, including travel expenses to and from the trial centre. PharmAust will also consider supporting ongoing post-trial maintenance treatment if both pet owners and vets consider this to be beneficial.
A number of dog owners have shared with us their MPL trial experience. Their feedback has been positive, and they are grateful to have been able to give their dog more time with their family and a good quality of life during their cancer journey.
Pet owners interested in enrolling their dogs in the MPL trial need to contact their veterinarian for a referral to their nearest trial centre.
Veterinarians – for questions about patient referrals or trial sites, please contact Principal Investigator, Dr Kim Agnew at kim@kapconsulting.com.au
For questions about the MPL trial program, please contact Dr Roger Aston, Executive Chairman of PharmAust Ltd on rogeraston@pharmaust.com
Dr Roger Aston currently serves as Executive Chairman of PharmAust. Dr Aston brings more than 20 years experience in the pharmaceutical and healthcare industries in senior roles in the UK, Asia Pacific and Australia. He has had extensive experience on boards and as Chief Executive Officer of many private and publicly listed biotechnology companies. During his career, he has been closely involved in start-up companies and major pharmaceutical companies. Aspects of his experience include FDA and EU product registration, clinical trials, global licensing agreements, fundraising through private placements, and a network of contacts within the pharmaceutical, banking and stock broking sectors. Dr Aston holds a B.Sc. (Hons) and Ph.D. degrees from the University of Manchester from 1975 to 1981.
Connect with Roger:
The future of veterinary care isn’t coming. It’s already here. The question is, are you ready to make the most of it? The pace of technological progress has never been faster. AI, automation, and integrated software solutions are transforming every industry, including...
